Preclinical development of novel PD-L1 tracers and first-in-human study of [ 68 Ga]Ga-NOTA-RW102 in patients with lung cancers
Journal for ImmunoTherapy of Cancer · 2024
DOI: 10.1136/jitc-2024-008794 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von You Zhang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, …. Hauptthemen laut MEDLINE: B7-H1 Antigen, Carcinoma, Non-Small-Cell Lung, Heterocyclic Compounds, 1-Ring, Lung Neoplasms. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health, National Key Research and Development Program of China.
Abstract (Originalsprache)
Background
The programmed cell death protein-1 (PD-1)/programmed death receptor ligand 1 (PD-L1) axis critically facilitates cancer cells’ immune evasion. Antibody therapeutics targeting the PD-1/PD-L1 axis have shown remarkable efficacy in various tumors. Immuno-positron emission tomography (ImmunoPET) imaging of PD-L1 expression may help reshape solid tumors’ immunotherapy landscape.
Methods
By immunizing an alpaca with recombinant human PD-L1, three clones of the v ariable domain of the h eavy chain of h eavy-chain only antibody (VHH) were screened, and RW102 with high binding affinity was selected for further studies. ABDRW102, a VHH derivative, was further engineered by fusing RW102 with the albumin binder ABD035. Based on the two targeting vectors, four PD-L1-specific tracers ([ 68 Ga]Ga-NOTA-RW102, [ 68 Ga]Ga-NOTA-ABDRW102, [ 64 Cu]Cu-NOTA-ABDRW102, and [ 89 Zr]Zr-DFO-ABDRW102) with different circulation times were developed. The diagnostic efficacies were thoroughly evaluated in preclinical solid tumor models, followed by a first-in-human translational investigation of [ 68 Ga]Ga-NOTA-RW102 in patients with non-small cell lung cancer (NSCLC).
Results
While RW102 has a high binding affinity to PD-L1 with an excellent K D value of 15.29 pM, ABDRW102 simultaneously binds to human PD-L1 and human serum albumin with an excellent K D value of 3.71 pM and 3.38 pM, respectively. Radiotracers derived from RW102 and ABDRW102 have different in vivo circulation times. In preclinical studies, [ 68 Ga]Ga-NOTA-RW102 immunoPET imaging allowed same-day annotation of differential PD-L1 expression with specificity, while [ 64 Cu]Cu-NOTA-ABDRW102 and [ 89 Zr]Zr-DFO-ABDRW102 enabled longitudinal visualization of PD-L1. More importantly, a pilot clinical trial shows the safety and diagnostic value of [ 68 Ga]Ga-NOTA-RW102 immunoPET imaging in patients with NSCLCs and its potential to predict immune-related adverse effects following PD-L1-targeted immunotherapies.
Conclusions
We developed and validated a series of PD-L1-targeted tracers. Initial preclinical and clinical evidence indicates that immunoPET imaging with [ 68 Ga]Ga-NOTA-RW102 holds promise in visualizing differential PD-L1 expression, selecting patients for PD-L1-targeted immunotherapies, and monitoring immune-related adverse effects in patients receiving PD-L1-targeted treatments. Trial registration number NCT06165874 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Department of Thoracic Surgery,Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, China.
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin, USA.
- Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
- Department of Thoracic Surgery, Huashan Hospital Fudan University, Shanghai, China.
ORCID-Profile: Haitao Zhao, Weijun Wei
Förderung
- NCI NIH HHS
- National Institutes of Health
- National Key Research and Development Program of China
- University of Wisconsin – Madison
- National Natural Science Foundation of China
Zitieren
APA
Zhang, Y., Cao, M., Wu, Y., Malih, S., Xu, D., Yang, E., Younis, M. H., Lin, W., Zhao, H., Wang, C., Liu, Q., Engle, J. W., Rasaee, M. J., Guan, Y., Huang, G., Liu, J., Cai, W., Xie, F., & Wei, W. (2024). Preclinical development of novel PD-L1 tracers and first-in-human study of [ 68 Ga]Ga-NOTA-RW102 in patients with lung cancers. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-008794
Vancouver
Zhang Y, Cao M, Wu Y, Malih S, Xu D, Yang E, et al. Preclinical development of novel PD-L1 tracers and first-in-human study of [ 68 Ga]Ga-NOTA-RW102 in patients with lung cancers. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2024-008794
BibTeX
@article{Zhang2024,
author = {Zhang, You and Cao, Min and Wu, Yanfei and Malih, Sara and Xu, Dong and Yang, Erpeng and Younis, Muhsin H and Lin, Wilson and Zhao, Haitao and Wang, Cheng and Liu, Qiufang and Engle, Jonathan W and Rasaee, Mohammad J and Guan, Yihui and Huang, Gang and Liu, Jianjun and Cai, Weibo and Xie, Fang and Wei, Weijun},
title = {Preclinical development of novel PD-L1 tracers and first-in-human study of [ 68 Ga]Ga-NOTA-RW102 in patients with lung cancers},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
doi = {10.1136/jitc-2024-008794}
}
EUVIMED